Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACH
ACH logo

ACH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Accendra Health Inc (ACH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.830
1 Day change
4.43%
52 Week Range
4.690
Analysis Updated At
2026/05/21
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ACH is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock is trading below its pivot level with weak momentum, no recent news catalyst, and no strong proprietary buy signal. While analysts have recently raised price targets and some remain bullish, the current technical setup does not support an immediate buy.

Technical Analysis

Current price is 2.71, slightly above the previous close of 2.67, with the market up 1.50% on the session. The trend is weak: MACD histogram is negative at -0.139 and still contracting, which signals limited upside momentum. RSI_6 at 26.981 is near oversold territory but is labeled neutral in the provided data, so it does not confirm a strong reversal. Moving averages are converging, suggesting the stock is in a compression phase rather than a confirmed uptrend. Price is below the pivot level of 3.446 and only slightly above S1 at 2.64, indicating the stock is sitting near support rather than breaking out. The pattern-based estimate suggests only a small short-term decline next day/week and a 6.23% gain over the next month, which is modest but not strong enough for an impatient long-term entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish based on the very low put-call ratios. Open interest put-call ratio at 0.09 and option volume put-call ratio at 0.03 show call dominance and a strong tilt toward bullish positioning. Call open interest is 33,465 versus put open interest of 2,926, reinforcing bullish sentiment. However, options activity alone is not enough to override the weak technical setup. Implied volatility is elevated at 92.73 with historical volatility at 97.08, but IV rank at 29.34 and IV percentile at 44.21 suggest volatility is not at an extreme premium relative to its recent range. Overall, options traders are leaning bullish, but price action has not confirmed that view yet.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
7

Positive Catalysts

  • The option market also shows strong call-skewed sentiment, which can support a rebound if momentum improves. The stock is also near support around 2.64, which could attract buyers if a short-term base forms.

Neutral/Negative Catalysts

  • There is no news in the recent week, so there is no clear event-driven catalyst. Technical momentum is weak, with a negative MACD histogram and no confirmed uptrend. The stock remains below the pivot level, and the expected near-term move is limited. Hedge funds and insiders are both neutral, and there is no recent congress trading data or notable politician activity to provide a bullish catalyst.

Financial Performance

No financial snapshot was available due to an error, so latest-quarter revenue, earnings, and margin trends cannot be confirmed. Because the latest quarter season is not provided, there is no reliable quarter-specific financial readout to support a buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment has improved recently. On 2026-05-12, UBS raised its price target to $4.50 from $3 and kept a Neutral rating, Citi raised its target to $5 from $3.25 and kept a Buy rating, and Baird raised its target to $6 from $5 and kept an Outperform rating. Earlier in February, Citi and UBS had lowered targets, so the trend has recently turned more constructive. Wall Street pros are mixed but slightly positive overall: the bullish side is that multiple firms raised targets and maintain Buy/Outperform ratings, while the cautious side is that UBS still only rates it Neutral and the stock has not yet shown confirming price strength.

Wall Street analysts forecast ACH stock price to rise
3 Analyst Rating
Wall Street analysts forecast ACH stock price to rise
1 Buy
1 Hold
1 Sell
Hold
Current: 2.710
sliders
Low
2.5
Averages
3.5
High
4
Current: 2.710
sliders
Low
2.5
Averages
3.5
High
4
UBS
Neutral
maintain
$3
AI Analysis
2026-05-12
Reason
UBS
Price Target
$3
AI Analysis
2026-05-12
maintain
Neutral
Reason
UBS raised the firm's price target on Accendra Health to $4.50 from $3 and keeps a Neutral rating on the shares.
Citi
NULL -> Buy
upgrade
$5
2026-05-12
Reason
Citi
Price Target
$5
2026-05-12
upgrade
NULL -> Buy
Reason
Citi raised the firm's price target on Accendra Health to $5 from $3.25 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACH
Unlock Now

People Also Watch